ETCTN Trials by Disease/Treatment Area: Skin and Other Melanoma

Skin and Other Melanoma

- Basal cell carcinoma
- Basal cell carcinoma
- BRAF-mutant melanoma
- Metastatic melanoma, not otherwise specified
- Kidney transplant recipients

BRAF-mutant melanoma

- Kidney transplant recipients with melanoma, basal cell carcinoma, Merkel cell carcinoma, cutaneous squamous cell carcinoma or MSI-high cancer

10057: A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors

9466: Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumors (Phase I only)

10214: Immune Checkpoint Blockade for Kidney Transplant Recipients with Selected Unresectable or Metastatic Cancers

* 10285: Phase 1 Study of an EZH2 Inhibitor (Tazemetostat) in Combination with Dual BRAF/MEK Inhibition in Patients with BRAF- Mutated Metastatic Melanoma who Progressed on Prior BRAF/MEK Inhibitor Therapy

▼ 9676: A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients with Advanced Solid Tumors (Expansion phase, Pt. 1 includes melanoma, renal cell, ovarian, and colorectal cancer)

NOTE: * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: April 17, 2020